Leo Pharma elaborates on 2030 strategy after new capital injection

Backed by Nordic Capital, Leo Pharma is now free to power ahead with the strategy that will ideally lead to Leo Pharma becoming a global, leading player in medical dermatology by 2030, according to CEO Catherine Mazzacco.

Photo: Leo Pharma / PR

The reason why Leo Pharma is gaining new capital through divesting parts of its ownership is very specific.

DKK 3.4bn (USD 543.0m) will be put towards supporting the strategic goals which Leo Pharma unveiled for the first time in August last year, states company President & CEO Catherine Mazzacco to MedWatch.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

In a world of options, Genmab's CEO chose partnerships

In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.

Analyst predicts slow start for Leo Pharma's Adtralza in UK

The take-up of Leo Pharma’s atopic eczema drug Adtralza in the UK will be slow-going, according to analyst bureau Global Data, after the British institute NICE released draft guidance where it was not recommend it as a standard treatment in England and Wales.

Further reading

Related articles

Latest news

See all jobs